Research & Development

GSK to buy oncology-focused biopharmaceutical firm Tesaro for $5.1bn

British drugmaker GlaxoSmithKline (GSK) has agreed to acquire US-based oncology-focused biopharmaceutical firm, Tesaro, for around £4bn ($5.1bn).

Biopharmaceutical firm Aprea Therapeutics raises €50m in financing

Aprea Therapeutics, a biopharmaceutical company engaged in the discovery and development of anticancer compounds that reactivate the tumor suppressor protein, p53, has closed a €50m Series C financing round.

WuXi, ABL Bio to collaborate on multiple bispecific antibodies

WuXi Biologics and ABL Bio have entered into an exclusive development and clinical manufacturing partnership for multiple bispecific antibodies.

AbCellera, Autolus partner on antibody discovery project

AbCellera, a privately held company that engages in partnerships to discover and develop next-generation therapeutic antibodies, has collaborated with clinical stage biopharmaceutical company Autolus Therapeutics on antibody discovery project.

HOOKIPA, DarwinHealth to collaborate on immunotherapies development

HOOKIPA Pharma has signed a research collaboration and license agreement with DarwinHealth to develop immunotherapies based on the systematic discovery and prioritization of the next generation of immunogenic, tumor-specific cryptic antigens.

BeiGene acquires rights to Zymeworks’ ZW25 and ZW49 bispecific candidates in Asia-Pacific

Zymeworks and BeiGene have entered into a collaboration for the clinical development and commercialization of the former’s investigational ZW25 and ZW49 HER2-targeted bispecific antibodies.

Roche’s Genentech agrees to buy Jecure Therapeutics

Roche Group’s member Genentech has agreed to acquire US-based biotechnology firm, Jecure Therapeutics, for an undisclosed sum.

Cyclica, Bayer partner to advance drug discovery programs

Cyclica has partnered with Bayer to drives drug discovery through artificial intelligence (AI)-augmented integrated network of cloud-based technologies.

Vineti, Tessa partner to advance cancer immunotherapies

Vineti has entered into a new partnership with Tessa Therapeutics to advance and scale personalized cell therapies for solid tumors in Asia and world-wide.